The year is still young, but we’ve already seen acquisitions of Ariad and CoLucid. Which biotechs could be scooped up next in 2017? Here’s why Clovis Oncology (NASDAQ: CLVS), Intercept Pharmaceuticals (NASDAQ: ICPT), and Jazz Pharmaceuticals (NASDAQ: JAZZ) could be at the top of the list.
Image source: Getty Images.